---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-031467"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2024-03-14T23:59:59+00:00"
generated_at: "2026-06-04T19:06:18.973738+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Larimar reports positive Phase 2 data for nomlabofusp; $161.6M financing extends runway into 2026

## Summary
- Phase 2 dose exploration study met endpoints: dose-dependent frataxin increases in skin and buccal cells; 50 mg cohort saw levels >33% of healthy volunteers in all patients at Day 14.
- FDA discussions initiated for using tissue frataxin as surrogate endpoint for accelerated approval; BLA submission targeted for 2H 2025.
- Open-label extension (OLE) study of 25 mg daily nomlabofusp dosed first patient in March 2024; interim data expected Q4 2024.
- Raised $161.6M net proceeds from public offering in Feb 2024; cash position $86.8M at Dec 31, 2023 before offering.
- Q4 2023 net loss $13.0M ($0.30/share) vs $9.4M ($0.21/share) in Q4 2022; R&D expenses $10.6M.

## SEC filing metadata
- accession: 0000950170-24-031467
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2024-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/0000950170-24-031467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/lrmr-20240314.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-031467
- JSON: https://secwatch.observer/filing/0000950170-24-031467.json
- Plain text: https://secwatch.observer/filing/0000950170-24-031467.txt

## Key facts
- Earnings Releases
  Larimar Therapeutics, Inc. reported the fourth quarter of 2023 and for the year ended December 31, 2023 results: net income $13.0 million, EPS $0.30 per share.
  - Period: the fourth quarter of 2023 and for the year ended December 31, 2023
  - Net income: $13.0 million
  - EPS: $0.30 per share
  - Result: reported results
  source text: The Company reported a net loss for the fourth quarter of 2023 of $13.0 million, or $0.30 per share, compared to a net loss of $9.4 million, or $0.21 per share, for the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374690/000095017024031467/0000950170-24-031467-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.